However, all Big Pharma companies including Swiss Roche AG have licenced obesity candidates to participate in the obesity market race
Chatterjee, Nutrients 5, 525 (2013) , E.V
According to a comprehensive aggregation of all the scientific data on BPC-157 to date, the following benefits have been observed in rats [2]: Exerts protective effects during damaging surgical procedures or administration of a toxic substance Heals organ, bone, and joint damage Treats stomach ulcers Possesses anti-inflammatory properties While the side effects of BPC-157 appear to be non-existent, very little research involving human test subjects exists [3]: While BPC-157 is not approved by the FDA, it can be purchased by researchers and, in rare cases, can be prescribed by a doctor in certain circumstances
Therapy effect of the stable gastric pentadecapeptide BPC 157 on acute pancreatitis as vascular failure-induced severe peripheral and central syndrome in rats
A Phase 1b study first established that co-administering cagrilintide with semaglutide 2.4 mg was tolerable and characterized cagrilintides pharmacokinetics, including its multi-day half-life of roughly 159195 hours
